batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. ESMO 2024 – Bristol abandonment overshadows Immatics 17 September 2024 ESMO 2024 – Amgen’s PRMT5 still looks lacklustre 17 September 2024 ESMO 2024 – Bristol bucks the degrader trend 16 September 2024 ESMO 2024 – how Merck overreached in endometrial 14 September 2024 ESMO 2024 – Astra’s B7-H4 effort underwhelms 14 September 2024 ESMO 2024 – no hiding Truqap’s triple-negative flop 13 September 2024 Accelerated path closes for Moderna/Merck’s immunotherapy 12 September 2024 Adicet's cancer U-turn 11 September 2024 Load More